Chapter 6 — Key Takeaways

The Peptide Hype Cycle

The core claims

The pipeline has five stages and nobody has to lie: a real preclinical result → an n-of-1 testimonial → a gray market operating under a legal fiction → media coverage in the miracle or menace register → a search result where sales pages outrank the primary literature. Each stage loses information the next cannot recover.

The most honest sentence in the pipeline is the authors' own limitations paragraph — and it is the first thing lost. When a claim cites a study, go read that paragraph. Two minutes, no statistical training required, frequently the whole answer.

Testimonials fail for five separable reasons: regression to the mean, natural history, expectation, co-intervention, and — the structural one — survivorship filtering, which operates on the record you see rather than on the person reporting.

"Research chemical — not for human consumption" is epistemic laundering. The vendor sells a reagent, the forum shares experience, the influencer describes a protocol. No participant states the therapeutic claim; collectively it has been made. Each element is defensible; the assembly is the claim.

Media fails in both registers. Miracle and menace are both more engaging than the truth, and the menace version does specific damage — it teaches a reader who is already using something that mainstream coverage does not understand them, discrediting the accurate parts along with the rest. Contempt is not a communication strategy.

Follow the money and the structural problem appears: no participant benefits from accurate uncertainty. "We don't know yet" sells nothing, ranks poorly, and satisfies nobody — including the author of this book.

And intelligent people are the vector, not the exception. Curiosity, institutional skepticism, willingness to read primary sources, and mechanistic knowledge are virtues that in this environment become the failure mode. Understanding how something would work makes it feel more likely to work, and knowing that does not switch it off.

The three cases, in one line each

Compound Genuinely true Where the distortion enters
BPC-157 Substantial, often well-conducted rodent literature across multiple models Volume of animal work presented as though it accumulated into human evidence
NAD+ precursors Real biochemistry; the precursors demonstrably do raise NAD+ in humans A moving surrogate presented as a demonstrated benefit; model-organism results presented as human ones
GHK-Cu Genuine, decades-old wound-healing and matrix-biology science Laboratory findings cited as cosmetic efficacy, with the delivery question — the decisive one — unaddressed

The pattern: in every case the underlying science is real, and the distortion enters at one identifiable step. Hype is usually a real finding with a step removed. Finding the missing step is the skill.

Evidence ratings issued in this chapter

Claim Rating Why What would change it
NAD+ precursors extend healthspan or produce meaningful functional benefit in humans ⚠️ trending ❌ for the strong version Real biochemistry and a genuinely moving surrogate, but human trials mostly small, short, and inconsistent on functional endpoints An adequately powered, long-duration RCT with a pre-specified functional or clinical endpoint
Topical GHK-Cu meaningfully improves the appearance of aging skin ⚠️ for modest instrument-measured effects; ❌ for the strong marketing version Genuine underlying science; unresolved penetration of intact stratum corneum; cosmetic studies small, short, industry-funded, instrument-based A randomized, vehicle-controlled trial with blinded assessment of appearance as the pre-specified endpoint

Note why NAD+ is ⚠️ and BPC-157 is ❌: human trials exist for NAD+ and are unimpressive, rather than absent. That is a stronger epistemic position and a worse commercial one, and the rating system distinguishes them deliberately.

The sixty-second first response

  1. WHAT IS THE SPECIFIC CLAIM?   for what, in whom, on what endpoint     [10 sec]
  2. WHAT RUNG?                    RCT / observational / animal / cell /
                                   mechanism / anecdote                    [15 sec]
  3. WHO IS TELLING ME,            not disqualifying — it sets the weight  [10 sec]
     AND WHAT DO THEY SELL?
  4. WHAT WOULD FALSIFY IT?        if nothing could, STOP                  [15 sec]
  5. HOW WOULD IT GET THERE?       Ch 4's delivery filter, in one question [10 sec]

  Survives all five? Now invest the real time: primary source,
  limitations paragraph, registry check.

Key terms

hype cycle · n-of-1 · testimonial · survivorship bias · confirmation bias · motivated reasoning · research chemical · legal fiction · epistemic laundering · citation chain · availability heuristic · information asymmetry

What you can now evaluate

  • ✅ where in the pipeline a claim you are reading sits, and what it lost getting there
  • ✅ why a sincere, detailed testimonial is near-worthless — without concluding the person is lying
  • ✅ what a vendor page's infrastructure reveals that its disclaimer denies
  • ✅ who profits from each version of a story, and why nobody profits from the accurate one
  • ✅ your own susceptibility, and the procedural (not attitudinal) defenses against it
  • ✅ a new claim, triaged in under a minute

The one-sentence version

The peptide information environment is not a conspiracy — it is the predictable output of a system in which every participant behaves rationally and nobody is paid to say "we don't know yet."

Part I ends here. You have the molecule (Ch 1), the mechanism (Ch 2), the system (Ch 3), the delivery problem (Ch 4), the evidentiary method (Ch 5), and a map of the environment (Ch 6).

Next: Chapter 7 opens Part II with the gut biology that produced the most consequential drug class in a generation — and you are now equipped to be appropriately impressed by it rather than merely impressed.